Drug Trial Radar · NCT06148649
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
234
Actual
Start
Dec 10, 2023
Primary completion
Feb 27, 2025
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, parallel, placebo- and active comparator-controlled phase 2 trial to evaluate the efficacy, safety, pharmacokinetics and immunogenicity in subjects with T2DM. Patients treated with diet and exercise alone, or in combination with stable metformin monotherapy (≥1500 mg/day or maximum tolerated dose ≥1000 mg/ day.), will be enrolled. Approximately 225 participants will be randomized. The study includes four stages: screening period (up to 2 weeks), lead-in period (2 weeks), treatment period (12 weeks) and safety follow-up period (3 weeks after treatment).
Conditions
- Type 2 Diabetes
Interventions
HEC88473, Placebo, DulaglutideDrug
T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline of HbA1c at week 12Time frame: Baseline to week 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Shijiazhuang People's Hospital
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.